{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T06:59:52Z","timestamp":1786863592579,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.apsb.2021.06.006","type":"journal-article","created":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T19:04:48Z","timestamp":1623783888000},"page":"353-363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Light-controllable charge-reversal nanoparticles with polyinosinic-polycytidylic acid for enhancing immunotherapy of triple negative breast cancer"],"prefix":"10.1016","volume":"12","author":[{"given":"Lei","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4960-5898","authenticated-orcid":false,"given":"Zitong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangshi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dangge","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0574-6966","authenticated-orcid":false,"given":"Yaping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2021.06.006_bib1","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2021.06.006_bib2","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41467-019-08595-2","article-title":"Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer","volume":"10","author":"Merino","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2021.06.006_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.apsb.2021.06.006_bib4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clbc.2014.09.010","article-title":"The efficacy and safety of preoperative chemotherapy with triweekly abraxane and cyclophosphamide followed by 5-fluorouracil, epirubicin, and cyclophosphamide therapy for resectable breast cancer: a multicenter clinical trial","volume":"15","author":"Shigematsu","year":"2015","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.apsb.2021.06.006_bib5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejca.2018.10.015","volume":"106","author":"Schneeweiss","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.apsb.2021.06.006_bib6","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1158\/1078-0432.CCR-19-3507","article-title":"Tumor mutational burden and pten alterations as molecular correlates of response to PD-1\/L1 blockade in metastatic triple-negative breast cancer","volume":"26","author":"Barroso-Sousa","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2021.06.006_bib7","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ccell.2020.04.007","article-title":"Expanding the role for immunotherapy in triple-negative breast cancer","volume":"37","author":"Savas","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2021.06.006_bib8","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.apsb.2019.05.006","article-title":"Targeting peptide-decorated biomimetic lipoproteins improve deep penetration and cancer cells accessibility in solid tumor","volume":"10","author":"Tan","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2021.06.006_bib9","doi-asserted-by":"crossref","first-page":"E183","DOI":"10.1016\/S1470-2045(20)30154-6","article-title":"Pembrolizumab for triple-negative breast cancer","volume":"21","author":"Stirrups","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2021.06.006_bib10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41571-019-0216-2","article-title":"Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?.","volume":"16","author":"D'Abreo","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2021.06.006_bib11","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.apsb.2021.06.006_bib12","doi-asserted-by":"crossref","first-page":"2009765","DOI":"10.1002\/adfm.202009765","article-title":"Shape transformable strategies for drug delivery","volume":"31","author":"Jia","year":"2021","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.apsb.2021.06.006_bib13","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1039\/C7BM01025G","article-title":"Ultrafast charge-conversional nanocarrier for tumor-acidity-activated targeted drug elivery","volume":"6","author":"Liu","year":"2018","journal-title":"Biomater Sci"},{"key":"10.1016\/j.apsb.2021.06.006_bib14","doi-asserted-by":"crossref","first-page":"1801807","DOI":"10.1002\/advs.201801807","article-title":"A pH\/ROS cascade-responsive charge-reversal nanosystem with self-amplified drug release for synergistic oxidation-chemotherapy","volume":"6","author":"Dai","year":"2019","journal-title":"Adv Sci"},{"key":"10.1016\/j.apsb.2021.06.006_bib15","doi-asserted-by":"crossref","first-page":"1802808","DOI":"10.1002\/adma.201802808","article-title":"Responsive assembly of upconversion nanoparticles for pH-activated and near-infrared-triggered photodynamic therapy of deep tumors","volume":"30","author":"Li","year":"2018","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2021.06.006_bib16","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.apsb.2020.01.009","article-title":"Delivery strategies for macromolecular drugs in cancer therapy","volume":"10","author":"Guo","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2021.06.006_bib17","doi-asserted-by":"crossref","first-page":"1706719","DOI":"10.1002\/adma.201706719","article-title":"Implantable synthetic immune niche for spatiotemporal modulation of tumor-derived immunosuppression and systemic antitumor immunity: postoperative immunotherapy","volume":"30","author":"Phuengkham","year":"2018","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2021.06.006_bib18","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1002\/adma.201506312","article-title":"Inflammation-triggered cancer immunotherapy by programmed delivery of cpg and anti-PD1 antibody","volume":"28","author":"Wang","year":"2016","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2021.06.006_bib19","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41565-018-0342-5","article-title":"Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy","volume":"14","author":"Shae","year":"2019","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2021.06.006_bib20","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/s41587-019-0247-3","article-title":"Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation","volume":"37","author":"Miao","year":"2019","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2021.06.006_bib21","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1021\/acs.nanolett.6b01994","article-title":"Acid-activatable versatile micelleplexes for PD-L1 blockade enhanced cancer photodynamic immunotherapy","volume":"16","author":"Wang","year":"2016","journal-title":"Nano Lett"},{"key":"10.1016\/j.apsb.2021.06.006_bib22","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.apsb.2019.07.004","article-title":"Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity","volume":"10","author":"Deng","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2021.06.006_bib23","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1021\/acs.accounts.8b00665","article-title":"Nonviral gene delivery with cationic glycopolymers","volume":"52","author":"Van Bruggen","year":"2019","journal-title":"Accounts Chem Res"},{"key":"10.1016\/j.apsb.2021.06.006_bib24","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jconrel.2020.03.021","article-title":"Nanoparticle depots for controlled and sustained gene delivery","volume":"322","author":"Li","year":"2020","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.06.006_bib25","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1021\/acs.nanolett.9b00657","article-title":"Facile hydrophobization of siRNA with anticancer drug for non-cationic nanocarrier-mediated systemic delivery","volume":"19","author":"Xu","year":"2019","journal-title":"Nano Lett"},{"key":"10.1016\/j.apsb.2021.06.006_bib26","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.apsb.2020.10.005","article-title":"Small interfering RNA for cancer treatment:\u00a0overcoming hurdles in delivery","volume":"10","author":"Charbe","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2021.06.006_bib27","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1021\/acs.accounts.9b00292","article-title":"The chemistry of boronic acids in nanomaterials for drug delivery","volume":"52","author":"Stubelius","year":"2019","journal-title":"Accounts Chem Res"},{"key":"10.1016\/j.apsb.2021.06.006_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aba4024","article-title":"Engineering autologous tumor cell vaccine to locally mobilize antitumor immunity in tumor surgical bed","volume":"6","author":"Fang","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.apsb.2021.06.006_bib29","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/s41467-018-03915-4","article-title":"A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors","volume":"9","author":"Wang","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2021.06.006_bib30","doi-asserted-by":"crossref","first-page":"2007149","DOI":"10.1002\/adfm.202007149","article-title":"Metformin mediated PD-L1 downregulation in combination with photodynamic-immunotherapy for treatment of breast cancer","volume":"31","author":"Hu","year":"2021","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.apsb.2021.06.006_bib31","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/anie.201804882","article-title":"Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy","volume":"58","author":"Duan","year":"2019","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.apsb.2021.06.006_bib32","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1021\/acsnano.9b07212","article-title":"Smart nanovesicle-mediated immunogenic cell death through tumor microenvironment modulation for effective photodynamic immunotherapy","volume":"14","author":"Yang","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2021.06.006_bib33","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1080\/17435390.2020.1817598","article-title":"The nanomaterial-induced bystander effects reprogrammed macrophage immune function and metabolic profile","volume":"14","author":"Yuan","year":"2020","journal-title":"Nanotoxicology"},{"key":"10.1016\/j.apsb.2021.06.006_bib34","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41565-019-0485-z","article-title":"Enzyme-activatable polymer\u2013drug conjugate augments tumour penetration and treatment efficacy","volume":"14","author":"Zhou","year":"2019","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2021.06.006_bib35","doi-asserted-by":"crossref","first-page":"1906598","DOI":"10.1002\/smll.201906598","article-title":"Effects of nanoparticle electrostatics and protein\u2013protein interactions on corona formation: conformation and hydrodynamics","volume":"16","author":"Lee","year":"2020","journal-title":"Small"},{"key":"10.1016\/j.apsb.2021.06.006_bib36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.nantod.2016.04.008","article-title":"Surface charge critically affects tumor penetration and therapeutic efficacy of cancer nanomedicines","volume":"11","author":"Wang","year":"2016","journal-title":"Nano Today"},{"key":"10.1016\/j.apsb.2021.06.006_bib37","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1158\/1078-0432.CCR-13-2781","article-title":"Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors","volume":"20","author":"Nagato","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2021.06.006_bib38","doi-asserted-by":"crossref","first-page":"1902960","DOI":"10.1002\/adma.201902960","article-title":"Self-amplified drug delivery with light-inducible nanocargoes to enhance cancer immunotherapy","volume":"31","author":"Feng","year":"2019","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2021.06.006_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aau6584","article-title":"Engineering nanoparticles to locally activate T cells in the tumor microenvironment","volume":"4","author":"Wang","year":"2019","journal-title":"Sci Immunol"},{"key":"10.1016\/j.apsb.2021.06.006_bib40","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.apsb.2020.07.013","article-title":"The progress and perspective of nanoparticle-enabled tumor metastasis treatment","volume":"10","author":"Zhang","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2021.06.006_bib41","doi-asserted-by":"crossref","first-page":"1900927","DOI":"10.1002\/adma.201900927","article-title":"Light-triggered in situ gelation to enable robust photodynamic-immunotherapy by repeated stimulations","volume":"31","author":"Meng","year":"2019","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2021.06.006_bib42","doi-asserted-by":"crossref","first-page":"1904156","DOI":"10.1002\/adma.201904156","article-title":"Nanomedicine-based immunotherapy for the treatment of cancer metastasis","volume":"31","author":"Zhang","year":"2019","journal-title":"Adv Mater"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383521002185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383521002185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:51:52Z","timestamp":1761929512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383521002185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S2211383521002185"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2021.06.006","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Light-controllable charge-reversal nanoparticles with polyinosinic-polycytidylic acid for enhancing immunotherapy of triple negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2021.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}